COVID Monoclonal Antibody Treatment
REGEN-COV® (casirivimab and imdevimab)
First Choice offers Casirivimab/Imdevimab (REGEN-COV® by Regeneron Pharmaceuticals, Inc.)
On November 21, 2020, Regeneron Pharmaceuticals, Inc. received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational treatment cocktail consisting of 2 monoclonal antibodies, casirivimab and imdevimab. The EUA allows healthcare providers to administer casirivimab/imdevimab to non-hospitalized patients with confirmed COVID-19 who are experiencing mild to moderate symptoms and are at high risk for severe symptoms and hospitalization. It can also be used to prevent COVID-19 once you are exposed, especially if you are unvaccinated.
Monoclonal Antibodies Treatment is a prevention as well as a treatment option for mild to moderate COVID-19 illness for non-hospitalized people and is a way to lower the chance of progression to severe illness or hospitalization.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses and bacteria which can cause disease. Currently, there are three monoclonal antibody therapies approved for use under an Emergency Use Authorization, for non-hospitalized patients.
Given the scarcity of these medications, the Illinois Department of Public Health strongly recommends limiting the use of therapeutics for the following highest priority patients as below:
Those 50 years and over with at least one additional risk factor OR above the age of 12 years with at least 2 additional risk factors for progression to severe COVID-19 disease as described here and as below:
- Cerebrovascular disease
- Chronic kidney disease
- Chronic lung diseases limited to:
- Interstitial lung disease
- Pulmonary embolism
- Pulmonary hypertension
- Bronchopulmonary dysplasia
- COPD (chronic obstructive pulmonary disease)
- Chronic liver diseases limited to:
- Non-alcoholic fatty liver disease
- Alcoholic liver disease
- Autoimmune hepatitis
- Diabetes mellitus, type 1 and type 2
- Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies)
- Mental health disorders limited to:
- Mood disorders, including depression
- Schizophrenia spectrum disorders
- Obesity (BMI ≥30 kg/m2)
- Pregnancy and recent pregnancy
- Smoking, current and former
Our highly trained medical staff are here to help you feel better.
Offering A Choice
We answer to a higher standard to give you the best service and peace of mind.
Driving To Us in Naperville
Heading NORTH On Rt. 59
Turn right on Gowdey Road, which is one block north of North Aurora Road. First Choice is the first building on the left, on the corner of Rt. 59 and Gowdey Road. It is a two-story brick building, and we are on the first floor.
Heading SOUTH On Rt. 59
Turn left on Gowdey Road, which is one block north of North Aurora Road. First Choice is the first building on the left, on the corner of Rt. 59 and Gowdey Road. It is a two-story brick building, and we are on the first floor.